INSM
Insmed Incorporated · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.33M | $149.97M | n/a | −2 |
| Q2 2026 | 156 | -6 | 147.06M | $15.68B | +6 | −13 |
| Q1 2026 | 166 | +6 | 152.11M | $24.63B | +9 | −4 |
| Q4 2025 | 159 | -1 | 156.45M | $27.23B | +1 | −1 |
| Q3 2025 | 21 | +1 | 121.03M | $17.43B | +1 | −1 |
| Q2 2025 | 18 | +1 | 70.35M | $7.08B | +2 | −1 |
| Q1 2025 | 14 | -1 | 33.99M | $2.59B | n/a | −1 |
| Q4 2024 | 15 | 0 | 31.46M | $2.17B | +1 | −1 |
| Q3 2024 | 14 | -1 | 23.46M | $1.71B | n/a | −1 |
| Q2 2024 | 15 | n/a | 25.91M | $1.74B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 12.16M | n/a | $814.95M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 3.64M | n/a | $243.98M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 1.76M | n/a | $117.75M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 1.32M | n/a | $88.78M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 1.25M | n/a | $83.71M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 1.20M | n/a | $80.30M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 7 | Viking Global Investors ✦ | 1.04M | n/a | $69.41M | 0.3% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 938.43K | n/a | $62.88M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 9 | Point72 Asset Management ✦ | 858.30K | n/a | $57.51M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 10 | Citadel Advisors ✦ | 799.75K | n/a | $53.58M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 11 | Soros Fund Management ✦ | 470.70K | n/a | $31.54M | 1.0% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 288.55K | n/a | $19.33M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Two Sigma Investments ✦ | 107.74K | n/a | $7.22M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 60.53K | n/a | $4.06M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 15 | Duquesne Family Office ✦ | 20.00K | n/a | $1.34M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 664 holders, 192.22M shares, $30.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $3.10M
Director · 5.00K sh · $637,650
Officer · 239.85K sh · $31.96M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology